The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immunosuppression can alter the body's response to sepsis, leading to often varying and confounding clinical presentations that may create diagnostic uncertainty and delay in intervention.”
From Immunosuppression Masking a Urological Emergency: A Case Report of Bilateral Infected Obstructed Kidneys (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of the immune system in humans from infancy to old age
Simon, A. K., Hollander, G. A., & McMichael, A. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2014.3085 · Cited by 1,796
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
An aged immune system drives senescence and ageing of solid organs
Yousefzadeh, M. J., Flores, R. R., Zhu, Y., Schmiechen, Z. C., Brooks, R. W., Trussoni, C. E., Cui, Y., Angelini, L., Lee, K.-A., McGowan, S. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03547-7 · Cited by 972
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare
Mohr, A. E., Ortega-Santos, C. P., Whisner, C. M., Klein-Seetharaman, J., & Jasbi, P. (2024) · Biomedicines · doi:10.3390/biomedicines12071496 · Cited by 311
Kasper, L., König, A., Koenig, P.-A., Gresnigt, M. S., Westman, J., Drummond, R. A., Lionakis, M. S., Groß, O., Ruland, J., Naglik, J. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06607-1 · Cited by 297
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Research works printed but not linked: 124
- Rudd, 2020, Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study, Lancet, 395, 200, 10.1016/S0140-6736(19)32989-7 · DOI · Paper page
- Martinson, 2024, Prevalence of immunosuppression among US adults, JAMA, 331, 880, 10.1001/jama.2023.28019 · doi:10.1001/jama.2023.28019
- Tolsma, 2014, Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile, Chest, 146, 1205, 10.1378/chest.13-2618 · DOI
- Greenberg, 2018, Hospital volume of immunosuppressed patients with sepsis and sepsis mortality, Ann Am Thorac Soc, 15, 962, 10.1513/AnnalsATS.201710-819OC · doi:10.1513/annalsats.201710-819oc
- Vaidie, 2023, Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study, Crit Care, 27, 340, 10.1186/s13054-023-04626-z · DOI
- Skevaki, 2015, Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases, Clin Exp Immunol, 180, 165, 10.1111/cei.12578 · DOI · Paper page
- Lorenz, 2002, Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock, Arch Intern Med, 162, 1028, 10.1001/archinte.162.9.1028 · DOI · Paper page
- Thompson, 2014, Toll-like receptor 1 polymorphisms and associated outcomes in sepsis after traumatic injury: a candidate gene association study, Ann Surg, 259, 179, 10.1097/SLA.0b013e31828538e8 · DOI
- Fallerini, 2021, Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study, eLife, 10, 10, 10.7554/eLife.67569 · DOI · Paper page
- von Bernuth, 2008, Pyogenic bacterial infections in humans with MyD88 deficiency, Science, 321, 691, 10.1126/science.1158298 · DOI · Paper page
- Yao, 2024, The role of inflammasomes in human diseases and their potential as therapeutic targets, Signal Transduct Target Ther, 9, 10, 10.1038/s41392-023-01687-y · DOI · Paper page
- Zhong, 2022, NLRP3, NLRC4 and NLRC5 gene polymorphisms associate with susceptibility of pulmonary aspergillosis in non-neutropenic patients, J Clin Med, 11, 10.3390/jcm11071870 · DOI
- Faure, 2014, Pseudomonas aeruginosa type-3 secretion system dampens host defense by exploiting the NLRC4-coupled inflammasome, Am J Respir Crit Care Med, 189, 799, 10.1164/rccm.201307-1358OC · DOI · Paper page
- Skattum, 2011, Complement deficiency states and associated infections, Mol Immunol, 48, 1643, 10.1016/j.molimm.2011.05.001 · DOI · Paper page
- Skokowa, 2017, Severe congenital neutropenias, Nat Rev Dis Primers, 3, 10.1038/nrdp.2017.32 · DOI · Paper page
- Resnick, 2012, Morbidity and mortality in common variable immune deficiency over 4 decades, Blood, 119, 1650, 10.1182/blood-2011-09-377945 · doi:10.1182/blood-2011-09-377945
- Fischer, 2015, Severe combined immunodeficiencies and related disorders, Nat Rev Dis Primers, 1, 10.1038/nrdp.2015.61 · DOI · Paper page
- Vuscan, 2024, Trained immunity: general and emerging concepts, Immunol Rev, 323, 164, 10.1111/imr.13326 · DOI
- Lange, 2022, 100 years of Mycobacterium bovis bacille Calmette-Guérin, Lancet Infect Dis, 22, e2, 10.1016/S1473-3099(21)00403-5 · DOI · Paper page
- Jansen, 2023, Ex vivo and in vitro monocyte responses do not reflect in vivo immune responses and tolerance, J Innate Immun, 15, 174, 10.1159/000525572 · DOI
- Shankar-Hari, 2024, Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies, Lancet Respir Med, 12, 323, 10.1016/S2213-2600(23)00468-X · DOI
- Hotchkiss, 2019, Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab, Intensive Care Med, 45, 1360, 10.1007/s00134-019-05704-z · DOI · Paper page
- Shankar-Hari, 2020, Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?, Intensive Care Med, 46, 119, 10.1007/s00134-019-05814-8 · DOI
- Kwok, 2023, Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis, Nat Immunol, 24, 767, 10.1038/s41590-023-01490-5 · DOI · Paper page
- Brudecki, 2012, Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response, Infect Immun, 80, 2026, 10.1128/IAI.00239-12 · DOI · Paper page
- Wolk, 2000, Impaired antigen presentation by human monocytes during endotoxin tolerance, Blood, 96, 218, 10.1182/blood.V96.1.218 · DOI · Paper page
- van Amstel, 2023, Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes, Intensive Care Med, 49, 1360, 10.1007/s00134-023-07239-w · DOI
- Balintescu, 2023, Glycaemic control and sepsis risk in adults with type 1 diabetes, Diabetes Obes Metab, 25, 1942, 10.1111/dom.15060 · DOI
- Balintescu, 2022, Glycemic Control and risk of sepsis and subsequent mortality in type 2 diabetes, Diabetes Care, 45, 127, 10.2337/dc21-1050 · DOI
- Abu-Raya, 2020, Maternal immunological adaptation during normal pregnancy, Front Immunol, 11, 10.3389/fimmu.2020.575197 · DOI · Paper page
- Wang, 2013, Obesity and risk of sepsis: a population-based cohort study, Obesity, 21, E762, 10.1002/oby.20468 · DOI
- Torres, 2022, Sepsis-induced immunosuppression, Annu Rev Physiol, 84, 157, 10.1146/annurev-physiol-061121-040214 · DOI · Paper page
- Rubio, 2019, Current gaps in sepsis immunology: new opportunities for translational research, Lancet Infect Dis, 19, e422, 10.1016/S1473-3099(19)30567-5 · DOI · Paper page
- Venet, 2018, Advances in the understanding and treatment of sepsis-induced immunosuppression, Nat Rev Nephrol, 14, 121, 10.1038/nrneph.2017.165 · DOI · Paper page
- Tangye, 2022, Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee, J Clin Immunol, 42, 1473, 10.1007/s10875-022-01289-3 · DOI · Paper page
- Kerner, 2020, Inherited human IFN-γ deficiency underlies mycobacterial disease, J Clin Invest, 130, 3158, 10.1172/JCI135460 · DOI
- Constantine, 2019, Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, Immunol Rev, 287, 103, 10.1111/imr.12714 · DOI
- Kernan, 2022, Prevalence of pathogenic and potentially pathogenic inborn error of immunity associated variants in children with severe sepsis, J Clin Immunol, 42, 350, 10.1007/s10875-021-01183-4 · DOI
- Andreakos, 2022, A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection, Nat Immunol, 23, 159, 10.1038/s41590-021-01030-z · DOI
- Tsafaras, 2020, Advantages and limitations of the neonatal immune system, Front Pediatr, 8, 5, 10.3389/fped.2020.00005 · DOI · Paper page
- Banerjee, 2017, Age, exercise, and the outcome of sepsis, Crit Care, 21, 286, 10.1186/s13054-017-1840-9 · DOI
- Abel, 2024, Human determinants of age-dependent patterns of death from infection, Immunity, 57, 1457, 10.1016/j.immuni.2024.05.020 · DOI
- Bastard, 2021, Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths, Sci Immunol, 6, 10.1126/sciimmunol.abl4340 · DOI · Paper page
- Puel, 2008, Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6, J Immunol, 180, 647, 10.4049/jimmunol.180.1.647 · DOI · Paper page
- Puel, 2010, Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J Exp Med, 207, 291, 10.1084/jem.20091983 · DOI · Paper page
- Mohammad, 2017, Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis, J Rheumatol, 44, 1468, 10.3899/jrheum.160909 · DOI
- Ghembaza, 2020, Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases, Chest, 158, 2323, 10.1016/j.chest.2020.05.558 · DOI
- Li, 2023, Association of autoimmune diseases with the occurrence and 28-day mortality of sepsis: an observational and Mendelian randomization study, Crit Care, 27, 476, 10.1186/s13054-023-04763-5 · DOI
- Tektonidou, 2019, Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA, Rheumatology, 58, 1794, 10.1093/rheumatology/kez103 · DOI
- Tie, 2024, Genetic associations between autoimmune diseases and the risks of severe sepsis and 28-day mortality: a two-sample Mendelian randomization study, Front Med, 11, 10.3389/fmed.2024.1331950 · DOI
- Gotur, 2020, Sepsis outcomes in solid organ transplant recipients, Transpl Infect Dis, 22, 10.1111/tid.13214 · DOI
- Kalil, 2015, Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study, Clin Infect Dis, 60, 216, 10.1093/cid/ciu789 · DOI
- Bahr, 2015, Rapid access to comprehensive care may explain better outcomes in persons with sepsis with solid organ transplant versus those without solid organ transplant, Clin Infect Dis, 60, 1869, 10.1093/cid/civ167 · doi:10.1093/cid/civ167
- Podestà, 2021, Mesenchymal stromal cell therapy in solid organ transplantation, Front Immunol, 11, 10.3389/fimmu.2020.618243 · DOI
- Donnelly, 2016, Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis, Clin Infect Dis, 63, 186, 10.1093/cid/ciw295 · DOI
- Bartoletti, 2018, Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection, Transpl Infect Dis, 20, 10.1111/tid.12930 · doi:10.1111/tid.12930
- Kalil, 2015, Reply to Thomason et al and Bahr et al, Clin Infect Dis, 60, 1870, 10.1093/cid/civ169 · DOI
- Ackerman, 2023, Effect of sepsis on death as modified by solid organ transplantation, Open Forum Infect Dis, 10, 10.1093/ofid/ofad148 · DOI
- Protus, 2022, Sepsis affects kidney graft function and one-year mortality of the recipients in contrast with systemic inflammatory response, Front Med, 9, 10.3389/fmed.2022.923524 · DOI
- Boekhoud, 2024, Predictive performance of NEWS and qSOFA in immunocompromised sepsis patients at the emergency department, Infection, 52, 1863, 10.1007/s15010-024-02247-4 · DOI
- Richter, 2016, Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1667, 10.1136/annrheumdis-2015-207838 · DOI
- Kelesidis, 2011, Does rituximab increase the incidence of infectious complications? A narrative review, Int J Infect Dis, 15, e2, 10.1016/j.ijid.2010.03.025 · DOI · Paper page
- Athni, 2023, Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab, Ann Allergy Asthma Immunol, 130, 699, 10.1016/j.anai.2023.01.018 · DOI
- Hu, 2024, Hospital-treated infections and risk of disability worsening in multiple sclerosis, Ann Neurol, 96, 694, 10.1002/ana.27026 · DOI
- Stolk, 2020, Norepinephrine dysregulates the immune response and compromises host defense during sepsis, Am J Respir Crit Care Med, 202, 830, 10.1164/rccm.202002-0339OC · DOI · Paper page
- Hensley, 2019, Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations, Crit Care Med, 47, 1310, 10.1097/CCM.0000000000003896 · DOI
- Shvetsov, 2021, Association of sepsis mortality with specific cancer sites and treatment type: The Multiethnic Cohort Study, J Pers Med, 11, 146, 10.3390/jpm11020146 · DOI
- Williams, 2023, Cancer and sepsis, Clin Sci, 137, 881, 10.1042/CS20220713 · DOI
- Sereeaphinan, 2021, Mortality-associated clinical risk factors in patients with febrile neutropenia: a retrospective study, IJID Reg, 1, 5, 10.1016/j.ijregi.2021.09.002 · doi:10.1016/j.ijregi.2021.09.002
- Mhaskar, 2014, Colony-stimulating factors for chemotherapy-induced febrile neutropenia, Cochrane Database Syst Rev, 2014
- Francois, 2018, Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial, JCI Insight, 3, 10.1172/jci.insight.98960 · DOI · Paper page
- MacPhail, 2024, Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study, Crit Care, 28, 148, 10.1186/s13054-024-04932-0 · doi:10.1186/s13054-024-04932-0
- Reynolds, 2023, Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis, Blood Adv, 7, 5898, 10.1182/bloodadvances.2023010539 · DOI
- Cappell, 2023, Long-term outcomes following CAR T cell therapy: what we know so far, Nat Rev Clin Oncol, 20, 359, 10.1038/s41571-023-00754-1 · DOI · Paper page
- Kumar, 2015, Severe sepsis in hematopoietic stem cell transplant recipients, Crit Care Med, 43, 411, 10.1097/CCM.0000000000000714 · doi:10.1097/ccm.0000000000000714
- Satwani, 2017, A multicenter study of bacterial blood stream infections in pediatric allogeneic hematopoietic cell transplantation recipients: the role of acute gastrointestinal graft-versus-host disease, Biol Blood Marrow Transplant, 23, 642, 10.1016/j.bbmt.2017.01.073 · DOI
- Mori, 2018, Gastrointestinal graft-versus-host disease is a risk factor for postengraftment bloodstream infection in allogeneic hematopoietic stem cell transplant recipients, Biol Blood Marrow Transplant, 24, 2302, 10.1016/j.bbmt.2018.06.002 · DOI
- 1981, Pneumocystis pneumonia—Los Angeles, MMWR Morb Mortal Wkly Rep, 30, 250
- Grossman, 2002, CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?, Nat Med, 8, 319, 10.1038/nm0402-319 · DOI · Paper page
- Barbier, 2020, Management of HIV-infected patients in the intensive care unit, Intensive Care Med, 46, 329, 10.1007/s00134-020-05945-3 · DOI
- Huson, 2015, The effect of HIV infection on the host response to bacterial sepsis, Lancet Infect Dis, 15, 95, 10.1016/S1473-3099(14)70917-X · DOI
- Cribbs, 2015, Characteristics and outcomes of HIV-infected patients with severe sepsis: continued risk in the post-highly active antiretroviral therapy era, Crit Care Med, 43, 1638, 10.1097/CCM.0000000000001003 · DOI
- King, 2015, Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators, JAMA Surg, 150, 343, 10.1001/jamasurg.2014.2257 · DOI
- Chaka, 2020, Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting, Int J Infect Dis, 96, 276, 10.1016/j.ijid.2020.04.004 · DOI
- Leventogiannis, 2022, Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial, Cell Rep Med, 3
- Shankar-Hari, 2020, Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis, Intensive Care Med, 46, 619, 10.1007/s00134-019-05908-3 · DOI
- Heffernan, 2021, Host diagnostic biomarkers of infection in the ICU: where are we and where are we going?, Curr Infect Dis Rep, 23, 4, 10.1007/s11908-021-00747-0 · DOI
- Svaldi, 2001, Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients, Br J Haematol, 115, 53, 10.1046/j.1365-2141.2001.03083.x · doi:10.1046/j.1365-2141.2001.03083.x
- Christ-Crain, 2005, Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study, Crit Care, 9, R816, 10.1186/cc3885 · DOI · Paper page
- Liang, 2023, Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis, BMC Infect Dis, 23, 288, 10.1186/s12879-023-08262-4 · DOI
- Kumar, 2024, Multidrug-resistant sepsis: a critical healthcare challenge, Antibiotics, 13, 46, 10.3390/antibiotics13010046 · DOI · Paper page
- McCreery, 2020, Sepsis in immunocompromised patients without human immunodeficiency virus, J Infect Dis, 222, S156, 10.1093/infdis/jiaa320 · DOI
- Di Pasquale, 2019, Prevalence and etiology of community-acquired pneumonia in immunocompromised patients, Clin Infect Dis, 68, 1482, 10.1093/cid/ciy723 · DOI · Paper page
- Ramirez, 2020, Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies, Chest, 158, 1896, 10.1016/j.chest.2020.05.598 · DOI · Paper page
- Cheng, 2023, Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American Thoracic Society workshop report, Ann Am Thorac Soc, 20, 341, 10.1513/AnnalsATS.202212-1019ST · DOI
- Kwakernaak, 2024, Lymfoproliferatieve aandoeningen als uiting van een primaire immuundeficiëntie: herkenning, diagnostiek en behandeling, Ned Tijdschr Hematol, 21, 62
- Cajander, 2024, Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine, Lancet Respir Med, 12, 305, 10.1016/S2213-2600(23)00330-2 · DOI · Paper page
- Schefold, 2010, Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure, Intensive Care Med, 36, 1810, 10.1007/s00134-010-1965-7 · DOI
- Leijte, 2020, Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes, Crit Care, 24, 110, 10.1186/s13054-020-2830-x · DOI
- Pfortmueller, 2017, Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers, Intensive Care Med Exp, 5, 49, 10.1186/s40635-017-0163-0 · DOI
- Barrios, 2024, Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot, JCI Insight, 9, 10.1172/jci.insight.175785 · DOI
- Llitjos, 2024, Enhancing sepsis biomarker development: key considerations from public and private perspectives, Crit Care, 28, 238, 10.1186/s13054-024-05032-9 · DOI
- Li, 2022, Diagnostic value of metagenomic next-generation sequencing for pneumonia in immunocompromised patients, Can J Infect Dis Med Microbiol, 2022, 10.1155/2022/5884568 · DOI
- Unterberg, 2023, Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis, Crit Care, 27, 417, 10.1186/s13054-023-04713-1 · DOI
- Kalil, 2009, Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit, Crit Care Med, 37, 2350, 10.1097/CCM.0b013e3181a3aa43 · DOI · Paper page
- Osawa, 2009, Cytomegalovirus infection in critically ill patients: a systematic review, Crit Care, 13, R68, 10.1186/cc7875 · DOI · Paper page
- Lachmann, 2018, Hemophagocytic lymphohistiocytosis: potentially underdiagnosed in intensive care units, Shock, 50, 149, 10.1097/SHK.0000000000001048 · DOI
- Brands, 2021, Plasma ferritin as marker of macrophage activation-like syndrome in critically Ill patients with community-acquired pneumonia, Crit Care Med, 49, 1901, 10.1097/CCM.0000000000005072 · DOI
- La Rosée, 2019, Recommendations for the management of hemophagocytic lymphohistiocytosis in adults, Blood, 133, 2465, 10.1182/blood.2018894618 · DOI · Paper page
- Fan, 2023, Hyperferritinemic sepsis, macrophage activation syndrome, and mortality in a pediatric research network: a causal inference analysis, Crit Care, 27, 347, 10.1186/s13054-023-04628-x · DOI
- Davenport, 2016, Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study, Lancet Respir Med, 4, 259, 10.1016/S2213-2600(16)00046-1 · DOI · Paper page
- Scicluna, 2017, Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study, Lancet Respir Med, 5, 816, 10.1016/S2213-2600(17)30294-1 · DOI · Paper page
- Sweeney, 2018, Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters, Crit Care Med, 46, 915, 10.1097/CCM.0000000000003084 · DOI · Paper page
- Baghela, 2022, Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures, EBioMedicine, 75, 10.1016/j.ebiom.2021.103776 · DOI · Paper page
- Meisel, 2009, Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial, Am J Respir Crit Care Med, 180, 640, 10.1164/rccm.200903-0363OC · DOI · Paper page
- Nurmi, 2025, Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial, J Infect, 90, 10.1016/j.jinf.2025.106412 · DOI
- Fish, 2022, Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial, Intensive Care Med, 48, 1525, 10.1007/s00134-022-06869-w · DOI
- Kotsaki, 2022, ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol, BMJ Open, 12, 10.1136/bmjopen-2022-067251 · DOI
- 2022, A blood atlas of COVID-19 defines hallmarks of disease severity and specificity, Cell, 185, 916, 10.1016/j.cell.2022.01.012 · DOI · Paper page
- Taplitz, 2018, Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update, J Clin Oncol, 36, 3043, 10.1200/JCO.18.00374 · DOI · Paper page
- Kamboj, 2024, Vaccination of adults with cancer: ASCO guideline, J Clin Oncol, 42, 1699, 10.1200/JCO.24.00032 · DOI
- Oh, 2023, Prior evaluation of nutritional status and mortality in patients with sepsis in South Korea, Nutrients, 15, 10.3390/nu15245040 · DOI
- Becker, 2009, Surviving sepsis in low-income and middle-income countries: new directions for care and research, Lancet Infect Dis, 9, 577, 10.1016/S1473-3099(09)70135-5 · DOI
- Nates, 2024, Septic shock in the immunocompromised cancer patient: a narrative review, Crit Care, 28, 285, 10.1186/s13054-024-05073-0 · DOI
Cited by
Abolanle, P., & Eylert, M. (2025) · Cureus · doi:10.7759/cureus.97923 · Cited by 1
Metadata
- Authors
- Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., Weigand, M. A., Cajander, S., Giamarellos-Bourboulis, E. J., Lachmann, G., Girardis, M., Scicluna, B. P., Ferrer, R., Payen, D., Weis, S., Torres, A., Bermejo-Martín, J. F., Osuchowski, M. F., Rubio, I., & Bouma, H. R.
- ORCID
- Deinhardt-Emmer, Stefanie
- Chousterman, Benjamin G
- Flohé, Stefanie B
- Skirecki, Tomasz
- Kox, Matthijs
- Winkler, Martin S
- Wiersinga, W Joost
- van der Poll, Tom
- Cajander, Sara
- Giamarellos-Bourboulis, Evangelos J
- Lachmann, Gunnar
- Girardis, Massimo
- Scicluna, Brendon P
- Ferrer, Ricard
- Payen, Didier
- Weis, Sebastian
- Torres, Antoni
- Bermejo-Martín, Jesús F
- Osuchowski, Marcin F
- Rubio, Ignacio
- Bouma, Hjalmar R
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2025-07
- Volume
- 13
- Issue
- 7
- Pages
- 623-637
- ISSN
- 2213-2600
- Cited by
- 64
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. https://app.cochat.ai/papers/10.1016/s2213-2600(25)00124-9
- The paper
- Deinhardt-Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., Weigand, M. A., Cajander, S., Giamarellos-Bourboulis, E. J., Lachmann, G., Girardis, M., Scicluna, B. P., Ferrer, R., Payen, D., Weis, S., . . . Bouma, H. R. (2025). Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(25)00124-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.